
|Videos|May 2, 2022
Treatment Options for HER2+ Breast Cancer After Progression on Tucatinib
Experts discuss their choice of systemic therapies after a patient with metastatic HER2+ breast cancer and brain metastases progresses on tucatinib therapy.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
Pembrolizumab Monotherapy Improves PFS in Frontline dMMR Endometrial Cancer
2
Agenus Discontinues Phase 3 BATTMAN Trial in Metastatic MSS Colorectal Cancer
3
How Do Updated NCCN Guidelines and ctDNA Data Reshape MIBC Treatment?
4
01 Real-World Outcomes of Radiation Omission After Breast-Conserving Surgery in Older Women With Stage I ER-Positive Breast Cancer: A SEER Analysis (2000–2022)
5


























































